Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Minervax ApS logo — Developing a maternal vaccine for Group B Streptococcus

Minervax ApS

Developing a maternal vaccine for Group B Streptococcus

Founded 2010 Denmark Denmark 67 employees Venture round Total: $212.40M Biotechnology, Health Care +2

General Information

Company Name Minervax ApS
Founded Year 2010
Location Denmark Denmark
Founders / Decision Makers
Team member
Employees 67
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Minervax ApS. To contact Minervax ApS, visit minervax.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Minervax ApS

Minervax ApS is a biotechnology company headquartered in Denmark, founded in 2010. The company aims to develop a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threatening infections caused by Group B streptococcus (GBS). Their slogan "Developing a maternal vaccine for Group B Streptococcus" reflects their primary goal. GBS is a significant concern, being the leading cause of life-threatening infections in newborns and responsible for substantial negative outcomes in pregnancies globally. MinervaX's vaccine is based on adjuvanted proteins antigens, covering close to 100% of clinical GBS isolates, which shows promising potential. The annual impact of GBS is substantial, with 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage worldwide. This demonstrates the urgent need for an effective solution. The latest significant development for MinervaX is the €54.00M Venture Round investment on 11 October 2023. The investors involved in this round are Novo Holdings, Industrifonden, Sunstone Capital, OrbiMed, Wellington Partners, Adjuvant Capital, BB Pureos Bioventures, Sanofi Ventures, Trill Impact Ventures, and LF Investment, which highlights the confidence and support from key players in the industry. Overall, MinervaX's focus on addressing a critical healthcare challenge through innovative biotechnology, coupled with robust investor support, positions them as a compelling investment opportunity with the potential for significant social and financial impact.

Taxonomy: maternal vaccine, Group B Streptococcus, GBS prevention, pregnancy outcomes, life-threatening infections, adjuvanted proteins antigens, neonatal health, stillbirth prevention, preterm delivery prevention, newborn infections, neonatal invasive disease, neurological damage prevention

Funding Rounds & Investors (13)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round €54.00M 10
Novo Holdings Industrifonden Sunstone Capital
Novo Holdings, Industrifonden +8
11 Oct 2023
Debt Financing €50.00M 1
European Investment Bank
15 Dec 2022
Series C €22.00M 9
Industrifonden Sunstone Capital Wellington Partners
Industrifonden, Sunstone Capital +7
15 Dec 2022
Series B €47.40M 7
Industrifonden Sunstone Capital Wellington Partners
Industrifonden, Sunstone Capital +5
15 Dec 2020
Venture Round Undisclosed 1
LU Innovation
08 Sep 2020
Grant €4.40M 3
Novo Holdings Sunstone Capital Repair Impact Fund
Novo Holdings, Sunstone Capital +1
21 Jan 2019
Grant €6.00M 1
Innovation Fund Denmark
19 Sep 2016
Venture Round €2.20M 3
Novo Holdings Sunstone Capital
Novo Holdings, Sunstone Capital +1
15 Feb 2016
Venture Round kr22.00M 3
Novo Holdings Sunstone Capital Vaekstfonden
Novo Holdings, Sunstone Capital +1
08 Jan 2014
Venture Round Undisclosed 1
Seed Capital
Seed Capital
31 Dec 2011

View All 13 Funding Rounds

Minervax ApS Alternatives & Competitors

Minervax ApS vs
ReNewVax Ltd
ReNewVax Ltd United Kingdom

Our aim is to prevent life-threatening bacterial infections and combat antimicrobial resistance with...

4 employees
Biotechnology, Health Care

FAQ About Minervax ApS

Developing a maternal vaccine for Group B Streptococcus
Minervax ApS was founded in 2010.
Minervax ApS is headquartered in Denmark.
Minervax ApS operates in Biotechnology, Health Care, Health and Wellness and Life Sciences. Its work centres on maternal vaccine, Group B Streptococcus, GBS prevention and pregnancy outcomes.
Minervax ApS has approximately 67 employees.
Minervax ApS has completed 13 funding rounds, raising a total of $212.40M. The latest funding stage is Venture round.
Top alternatives and competitors to Minervax ApS include ReNewVax Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Minervax ApS and ReNewVax Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Minervax ApS, https://bouncewatch.com/company/minerva-aps, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes